Mr. McClellan, who was appointed to finance chief in 2017, reportedly is leaving the company for personal reasons that require him to be close to his family.
The departure comes as Teva works on a turnaround to improve its finances. This week the generic drugmaker reported a net loss of $698 million in the second quarter of 2019.
The drugmaker will be searching for a new finance chief amid high company debt levels, opioid litigation and a price-fixing investigation.
More articles on pharmacy:
2020 election brewing ‘perfect storm’ for drug-pricing reform, analyst says
Colombia fines Pfizer $25K for drug price inflation
Jefferson Healthcare opens retail specialty pharmacy
